Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine, groups A, C, Y and W135 (Walvax Biotechnology Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Yuxi Walvax MPV ACYW is a quadrivalent meningococcal polysaccharide vaccine developed by Walvax Biotechnology. It is indicated for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine contains purified capsular polysaccharides from each of the four serogroups and is administered via intramuscular injection. It is primarily used in pediatric and adult populations to provide protection against meningitis and septicaemia. In clinical trials, such as the Phase IV study NCT05441410, it has been evaluated for immunogenicity and safety in children aged 2 to 10 years, often compared against conjugate vaccines like Menactra to demonstrate its clinical profile in real-world settings.
- Brand names
- Yuxi Walvax MPV ACYWMPV ACYW
- Other names
- Meningococcal Polysaccharide Vaccine Groups A, C, Y and W135
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine, groups A, C, Y and W135 (Walvax Biotechnology Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine, groups A, C, Y and W135 (Walvax Biotechnology Co., Ltd.).